HomeCompareNKG vs MRK

NKG vs MRK: Dividend Comparison 2026

NKG yields 1.50% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $35.9K in total portfolio value
10 years
NKG
NKG
● Live price
1.50%
Share price
$10.10
Annual div
$0.15
5Y div CAGR
-12.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.8K
Annual income
$41.17
Full NKG calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — NKG vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNKGMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NKG + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NKG pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NKG
Annual income on $10K today (after 15% tax)
$127.25/yr
After 10yr DRIP, annual income (after tax)
$34.99/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $8,293.42/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NKG + MRK for your $10,000?

NKG: 50%MRK: 50%
100% MRK50/50100% NKG
Portfolio after 10yr
$38.8K
Annual income
$4,919.65/yr
Blended yield
12.68%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

NKG
Analyst Ratings
2
Hold
Consensus: Hold
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NKG buys
0
MRK buys
0
No recent congressional trades found for NKG or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNKGMRK
Forward yield1.50%2.76%
Annual dividend / share$0.15$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-12.6%32.7%
Portfolio after 10y$20.8K$56.8K
Annual income after 10y$41.17$9,798.13
Total dividends collected$790.00$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: NKG vs MRK ($10,000, DRIP)

YearNKG PortfolioNKG Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$10,831$130.84$11,206$366.19$375.00MRK
2$11,705$115.75$12,650$502.35$945.00MRK
3$12,626$102.18$14,407$694.19$1.8KMRK
4$13,600$90.03$16,585$967.82$3.0KMRK
5$14,631$79.21$19,342$1,363.89$4.7KMRK
6$15,725$69.61$22,913$1,947.19$7.2KMRK
7$16,887$61.11$27,662$2,823.89$10.8KMRK
8$18,123$53.60$34,159$4,173.35$16.0KMRK
9$19,438$46.99$43,337$6,308.80$23.9KMRK
10$20,840$41.17$56,776$9,798.13$35.9KMRK

NKG vs MRK: Complete Analysis 2026

NKGStock

Nuveen Georgia Quality Municipal Income Fund is a closed ended fixed income mutual fund launched by Nuveen Investments, Inc. The fund is co-managed by Nuveen Fund Advisors, LLC and Nuveen Asset Management, LLC. It invests in the fixed income markets of the Georgia. The fund invests into undervalued municipal securities and other related investments the income from which is exempt from regular federal and Georgia income taxes. It seeks to invest in investment grade securities with an average maturity of around 17 years. The fund employs fundamental analysis with a focus on bottom-up stock picking approach to create its portfolio. It benchmarks the performance of its portfolio against Standard & Poor's (S&P) Georgia Municipal Bond Index and Standard & Poor's (S&P) National Municipal Bond Index. The fund was formerly known as Nuveen Georgia Dividend Advantage Municipal Fund 2. Nuveen Georgia Quality Municipal Income Fund was formed on October 26, 2001 and is domiciled in the United States.

Full NKG Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this NKG vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NKG vs SCHDNKG vs JEPINKG vs ONKG vs KONKG vs MAINNKG vs JNJNKG vs ABBVNKG vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.